Results 151 to 160 of about 166,272 (252)

Multimodal AI‐Driven Identification of Dehydrocostus Lactone as a Potent Renal Fibrosis Attenuator Targeting IQGAP1

open access: yesAdvanced Science, EarlyView.
Renal fibrosis, a hallmark of CKD, lacks effective treatments. Herein, we developed a multimodal AI model (TCM‐SPred) to identify anti‐fibrotic agents and found that dehydrocostus lactone (DCL) targets IQGAP1 to inhibit Wnt signaling, blocking the interaction between IQGAP1 and CCT3, demonstrating potent anti‐fibrotic activity in vitro and in vivo ...
Weijiang Lin   +12 more
wiley   +1 more source

Trackable Tolerogenic Macrophages Integrate PD‐L1 and Rapamycin Signaling to Suppress Alloimmune Responses in Transplantation

open access: yesAdvanced Science, EarlyView.
We developed a macrophage‐based therapeutic platform, termed trackable tolerogenic macrophages (TTM), for dual‐function immunomodulation and visualization in vivo. TTM cells were engineered to overexpress PD‐L1, incorporate bioorthogonal cell surface tags, and load rapamycin for sustained release.
Yihui Wang   +14 more
wiley   +1 more source

RENAL‐CHIP: Rejection Evaluation via Non‐Invasive Analysis of Circulating Podocytes With Herringbone‐Chip Isolation Platform

open access: yesAdvanced Science, EarlyView.
RENAL‐CHIP converts 1 mL of peripheral blood into a biopsy‐equivalent readout of renal‐allograft fate. By magnetic capture and release of donor‐derived circulating podocytes through a herringbone microfluidic chip, 84% capture, 96% release and single‐cell RNA evidence of rejection‐specific immunity are achieved.
Juan Song   +11 more
wiley   +1 more source

AML‐Targeted Metal‐Polyphenol Nanoplatform Induces Ferroptosis‐ICD Cascade for Antitumor Immunity Boosting

open access: yesAdvanced Science, EarlyView.
Schematic illustration of the synthesis protocol for Fe‐SH@Fn, an AML‐targeted nanoplatform engineered to co‐deliver shikonin (SH) and Fe3+, synergistically boosting antitumor immunity via ferroptosis induction and immunogenic cell death (ICD). ABSTRACT Acute myeloid leukemia (AML) remains a therapeutic challenge due to its low immunogenicity and ...
Shangqin Yang   +9 more
wiley   +1 more source

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

open access: yesAdvanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy